Twenty-four weeks therapy with peginterferon alfa-2a could be similar to 48 weeks therapy in patients with HBeAg positive chronic hepatitis B and good predictors of response: Results of a pilot study;El tratamiento de 24 semanas con PEG interferón alfa 2a podría ser similar al de 48 semanas en pacientes con hepatitis B crónica HBeAg positivo y buenos predictores de respuesta: Resultados de un estudio piloto

Acta Gastroenterologica Latinoamericana

Volumn 39, Issue 4, 2009, Pages 254-260

  Solari, Joaquín ^a   Galdame, Omar ^a   Rezzonico, Lucrecia ^a   Frider, Bernardo ^b   Villamil, Alejandra ^a   Casciato, Paola ^a   Reig, María ^a   Bandi, Juan Carlos ^a   Alessio, Analía ^b   Gadano, Adrián ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^b HOSPITAL GENERAL DE AGUDOS DR COSME ARGERICH   (Argentina)

Author keywords

Hepatitis B; Peginterferon alfa 2a; Therapeutics

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; VIRUS DNA; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; ASTHENIA; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOTHERAPY; LIVER FIBROSIS; MALE; MIGRAINE; MULTICENTER STUDY; MYALGIA; PNEUMONIA; PSEUDOGOUT; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; BLOOD; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; HEPATITIS B, CHRONIC; IMMUNOLOGY; PILOT STUDY; PROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; PILOT PROJECTS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 73649099167     PISSN: 03009033     EISSN: 03009033     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004;350:1118-1129.
2. Gish RG, Gadano AC. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat 2006;13:787-798.
3. Hui CK, Leung N, Shek TW, Yao H, Lee WK, Lai JY, Lai ST, Wong WM, Lai LS, Poon RT, Lo CM, Fan ST, Lau GK, Hong Kong Liver Fibrosis Study Group. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology 2007;46:690-698.
4. Liaw Y-F, Leung N, Guan R, Lau GKK, Merican I, McCaughan G, Gane E, Kao J-H, Omata M, for the Asian-Pacific consensus update working party on chronic hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver International 2005; 25:472-489.
5. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539.
6. Martin P. Defining HBV resistance: interpreting and applying clinical data. Clinical Care Options, LLC. Copyright © 2007.
7. Chang T, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D, for the BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010.
8. Hui AY, Chan HL, Cheung AY, Cooksley G, Sung JJ. Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther 2005;22:519-528.
9. Cooksley G. The treatment of hepatitis B e antigen-positive chronic hepatitis B with pegylated interferon. J Hepatol 2003;39:S143-S145.
10. Lai L, Hui CK, Leung N, Lau GK. Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B. Int J Nanomedicine 2006;1:255-262.
11. Hui CK, Lau GK. Peginterferon-alpha2a (40 kDa) (Pegasys) for hepatitis B. Expert Rev Anti Infect Ther 2005;3:495-504.
12. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Häussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427.
13. Cooksley WGE, Piratvisuth T, Wang YJ, Mahachi V, Chao YC, Tanwandee T, Chutaputti A, Chang WY, Zahm FE, Pluck N. 40 Kd PegInterferon alpha 2A (Pegasys) efficacy and safety results, from a phase II, randomized actively controlled, multicenter study in the treatment of HBeAg positive chronic hepatitis B. American Association for the Study of Liver Disease, October 27-31, Dallas, TX, USA;2001.
14. Craxi A, Di Bona D, Cammà C. Interferon alpha for HBeAg positive chronic hepatitis B: systematic review. The European Association for the Study of the Liver. EASL International Consensus Conference on Hepatitis B. Geneva, September 13-14, 2002. Program and Manuscripts: 137-155.
15. Cooksley WGE, Piratvisuth T, Wang YJ, Mahachi V, Chao YC, Tanwandee T, Chutaputti A, Chang WY, Zahm FE, Pluck N. Evidence for the efficacy of PegInterferon alpha 2A (40Kd) (Pegasys) in the treatment of HBeAntigen positive chronic hepatitis B and impact of baseline factors. European Association for the Study of the Liver, Madrid, 19 April; 2002.
16. Kuhen KL, Vessey JW, Samuel CE. Mechanism of interferon action: identification of essential positions within the novel 15-base-pair KCS element required for transcriptional activation of the RNA-dependent protein kinase pkr gene. J Virol 1998;72:9934-9939.
17. Kuhen KL, Samuel CE. Mechanism of interferon action: functional characterization of positive and negative regulatory domains that modulate transcriptional activation of the human RNA-dependent protein kinase Pkr promoter. Virology 1999;254:182-195.
18. Asselah T, Lada O, Moucari R, Martinot M, Boyer N and Marcellin P. Interferon Therapy for Chronic Hepatitis B. Clin Liver Dis 2007;11:839-849.
19. Wiegand J, Hasenclever D, Tillman HL. Should treatment of hepatitis B depend on HBV genotypes? - a hypothesis generated from an explorative analysis of published evidence. Hepatology 2006;44(Suppl 1):564A-565A.
20. Cooksley WGE, Piratvisuth R, Lee S-D, Mahachai V, Chao Y-C, Tanwandee T, Chutaputti A, Chang WY, Zahm FE, Pluck N. Peginterferon a-2a (40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305.
21. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N, Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695.
22. Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy. J Gastroenterol Hepatol 2002;17:409-414.
23. Kowdley KV. Virologic monitoring in hepatitis B: tools for determining treatment candidacy and response. Clinical Care Options, LLC. Copyright © 2007 by the American Association for the Study of Liver Diseases. www.interscience.wiley.com
24. Thomas HC. Best practice in the treatment of chronic hepatitis B: a summary of the European Viral Hepatitis Educational Initiative (EVHEI). Journal of Hepatology 2007;47:588-597.
25. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006;4:936-962.
26. Hui CK, Lai LS, Lam P, Zhang HY, Fung TT, Lai ST, Wong WM, Lo CM, Fan ST, Leung N, Lau GK, Hong Kong Liver Fibrosis Study Group. 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection. Aliment Pharmacol Ther 2006;23:1171-1178.